Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 153 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Follow-Up Questions
Molecular Partners AG 的 CEO 是谁？
Dr. Patrick Amstutz 是 Molecular Partners AG 的 Chief Executive Officer，自 2006 加入公司。
MLLCF 股票的价格表现如何？
MLLCF 的当前价格为 $3.5，在上个交易日 decreased 了 0%。
Molecular Partners AG 的主要业务主题或行业是什么？
Molecular Partners AG 属于 Biotechnology 行业，该板块是 Health Care
